^
    3d
    PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1, N=12, Terminated, Henan Cancer Hospital | Phase classification: P1/2 --> P1 | Trial completion date: Feb 2025 --> Aug 2025
    Phase classification • Trial completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    Epidaza (chidamide) • parsaclisib (INCB50465)
    4d
    Chidamide enhances the sensitivity of gastric cancer to 5-fluorouracil chemotherapy by suppressing the HDAC3/HNF4A/TYMS axis. (PubMed, Cell Death Dis)
    Chidamide promoted the sensitivity of GC to 5-FU by suppressing the HDAC3/HNF4A/TYMS axis. This research may provide a foundation for using chidamide to counteract resistance to 5-FU in GC.
    Journal
    |
    TYMS (Thymidylate Synthetase) • HDAC3 (Histone Deacetylase 3) • HNF1A (HNF1 Homeobox A)
    |
    5-fluorouracil • Epidaza (chidamide)
    14d
    Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia (clinicaltrials.gov)
    P2, N=92, Recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)
    15d
    The efficacy and survival impact of chidamide on angioimmunoblastic T-cell lymphoma based on Epstein-Barr virus stratification in the real world: A multicenter study. (PubMed, Int J Cancer)
    EBV infection appears to influence disease progression and prognosis in EBER-positive patients, whereas EBER-negative cases more closely align with the disease characteristics observed in other peripheral T-cell lymphomas. The results suggest that stratifying patients by EBV status is crucial for optimizing AITL clinical management.
    Clinical • Journal • Real-world evidence
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    Epidaza (chidamide)
    17d
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) (clinicaltrials.gov)
    P3, N=218, Recruiting, Dizal Pharmaceuticals
    New P3 trial
    |
    gemcitabine • Epidaza (chidamide) • Beleodaq (belinostat) • Folotyn (pralatrexate) • golidocitinib (DZD4205)
    18d
    Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML (clinicaltrials.gov)
    P2, N=240, Recruiting, Guangdong Provincial People's Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • daunorubicin • idarubicin hydrochloride • mitoxantrone
    23d
    Epstein-barr virus-encoded small RNA incorporated prognostic model enables precision risk stratification and guides treatment decisions in peripheral t-cell lymphoma: a multicenter retrospective cohort. (PubMed, Ann Hematol)
    The model outperformed existing models and demonstrated excellent discrimination, stability, clinical utility across PTCL subgroups. This novel prognostic score, integrating subtype-specific marker and clinical features, provides a refined framework for precise PTCL risk stratification and treatment guidance.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule)
    |
    Epidaza (chidamide)
    1m
    A Prospective Study of Chidamide Combined with Venetoclax in the Treatment of Newly Diagnosed Adult T-Lymphoblastic Lymphoma/T-Cell Acute Lymphoblastic Leukemia (ChiCTR2500110820)
    P=N/A, N=20, Not yet recruiting, The Affiliated Hospital of Jining Medical University; The Affiliated Hospital of Jining Medical University
    New trial
    |
    Venclexta (venetoclax) • Epidaza (chidamide)
    1m
    A cohort, open-label, phase II clinical study of chidamide combined with tislelizumab and anlotinib in the treatment of advanced esophageal cancer (ChiCTR2500110497)
    P2, N=40, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New P2 trial
    |
    Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr) • Epidaza (chidamide)
    1m
    A Multicenter, Randomized, Two-Arm Clinical Study of Chidamide Combined with Sintilimab and S-1 or Irinotecan Liposome Combined with S-1 as Second-Line Therapy for Advanced Pancreatic Cancer (ChiCTR2500109834)
    P4, N=46, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P4 trial
    |
    Tyvyt (sintilimab) • Epidaza (chidamide) • Teysuno (gimeracil/oteracil/tegafur)
    1m
    Study on the Salvage and Preemptive Treatment of Myeloid Hematologic Diseases with PD-1 Monoclonal Antibody Combined with Chidamide and DLI After Allo-HSCT (ChiCTR2500109662)
    P2, N=15, Not yet recruiting, Chinese People's Liberation Army General Hospital; The First Medical Center of the Chinese People's Liberation Army General Hospital
    New P2 trial
    |
    Epidaza (chidamide)
    1m
    A prospective, single-center, single-arm clinical study evaluating the efficacy and safety of pralatrexate combined with chidamide and azacitidine in adult patients with newly diagnosed peripheral T-cell lymphoma (ChiCTR2500109351)
    P2, N=20, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    ALK negative
    |
    azacitidine • Epidaza (chidamide) • Folotyn (pralatrexate)